Jupiter, FL-based Envoy Therapeutics says it has struck a multi-year research collaboration deal with an affiliate of Merck to discover novel diabetes and obesity drug targets. Envoy will use its bacTRAP technology to identify proteins expressed specifically in certain cell types. Merck will then work to identify and develop compounds that modulate protein targets with therapeutic potential for the treatment of metabolic disorders. Envoy gets an upfront fee and research funds. Envoy release